07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Opalia Pharma S.A., Recordati deal

Recordati completed its acquisition of 90% of branded generics company Opalia. Specifically, Recordati acquired 23% of Opalia shares for about €5.9 million ($8 million). In October, Recordati acquired 67% of Opalia shares for €22.6 million...
08:00 , Jan 30, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Amgen's IBD gene hunt Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Ariana, Bruker, University Hospitals of Strasbourg, University of Strasbourg diagnostic news

Ariana launched its ExtempoNMR project, which is partnered with Bruker's Bruker Biospin subsidiary, the university and university hospitals, to develop a tool for in vitro cancerous tissue diagnosis during surgical procedures. The tool will be...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Opalia Pharma S.A., Recordati deal

Recordati said it acquired 90% of branded generics company Opalia in a deal valued at about €37 million ($48.6 million). Recordati estimates Opalia will have about €18.5 million ($24.3 million) in 2013 sales. Opalia markets...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Ariana bioinformatics, cancer news

Ariana joined the Worldwide Innovative Networking (WIN) Consortium to develop and commercialize personalized cancer medicine software through the WINTHER trial. In the trial, cancer patients will receive therapies chosen based on individual DNA, RNA and...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Company News

Ariana, CTI Biotech, Ipsen, Pierre Fabre, Oncodesign, Oncomedics, Transgene, Merieux NutriSciences Corp., Sanofi, Servier cancer news

The IMODI project has an expected budget of €41 million ($53.3 million), including €27.6 million ($35.9 million) in private investment. The pharmas include Sanofi, Servier, Ipsen, Pierre Fabre, Transgene and the Biofortis subsidiary of Merieux...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Ariana, Bio-Rad Laboratories, Beaujon Hospital, INSERM deal

Ariana, INSERM, the Beaujon Hospital and Bio-Rad partnered to discover biomarkers for liver fibrosis in HCV patients. Ariana will use its Knowledge Extraction and Management (KEM) platform to identify biomarkers and generate, assess and prioritize...
08:00 , Nov 21, 2005 |  BioCentury  |  Emerging Company Profile

Ariana Pharmaceuticals SA

Ariana Pharmaceuticals SA Ariana Pharmaceuticals SA Paris, France Technology: Artificial intelligence computational technology for lead optimization and toxicity prediction Disease focus: NA Clinical status: NA Founded: 2003 by Mohammad Afshar, Alain Commercon, Jean Sallantin and...
08:00 , Nov 21, 2005 |  BioCentury  |  Emerging Company Profile

Ariana: Juggling 5 balls at once

Ariana Pharmaceuticals SA is hoping that its computational technology will allow companies to speed up lead optimization and reduce failures due to toxicity by addressing five parameters simultaneously instead of sequentially: activity, absorption, stability, specificity...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Company News

Ariana Pharmaceuticals SA sales and marketing update

Ariana launched its Knowledge Extraction Management (KEM) methodology, which combines artificial intelligence and experimental methods to predict behavior of novel molecules. Ariana Pharmaceuticals SA , Paris, France   Business: Bioinformatics, Chemistry, Supply/Service  ...